Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies

Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death. Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries. Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death. Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time. Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.

[1]  J Stover,et al.  The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds , 2008, Sexually Transmitted Infections.

[2]  K. Anastos,et al.  Antiretroviral therapy in resource‐limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub‐Saharan Africa, Asia and Latin America , 2008, Tropical medicine & international health : TM & IH.

[3]  K. Nelson,et al.  The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up , 2007, AIDS.

[4]  N. Sewankambo,et al.  Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda , 2007, AIDS.

[5]  L. Shafer,et al.  HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda , 2007, AIDS.

[6]  P. Sonnenberg,et al.  Estimating ‘net’ HIV-related mortality and the importance of background mortality rates , 2007, AIDS.

[7]  Basia Zaba,et al.  Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. , 2007, AIDS.

[8]  Jim Todd,et al.  Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy , 2007, AIDS.

[9]  K. Nelson,et al.  Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992–2007 , 2007, AIDS.

[10]  T. Bärnighausen,et al.  Age-specific mortality patterns in HIV-infected individuals: a comparative analysis of African community study data , 2007, AIDS.

[11]  R. Salamon,et al.  Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire. , 2007, Bulletin of the World Health Organization.

[12]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[13]  J. Salomon,et al.  The Global Impact of Scaling Up HIV/AIDS Prevention Programs in Low- and Middle-Income Countries , 2006, Science.

[14]  N. Walker,et al.  Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. , 2006, Bulletin of the World Health Organization.

[15]  L. Myer,et al.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.

[16]  M. Egger,et al.  Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. , 2005, International journal of epidemiology.

[17]  V. Robison,et al.  HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. , 2005, International journal of epidemiology.

[18]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[19]  L. Bekker,et al.  Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines , 2004, AIDS.

[20]  M. Robb,et al.  The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion , 2004, Journal of acquired immune deficiency syndromes.

[21]  G. Swingler,et al.  Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. , 2003, The Cochrane database of systematic reviews.

[22]  H. Whittle,et al.  Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia , 2002, AIDS.

[23]  L. Stewart,et al.  To IPD or not to IPD? , 2002, Evaluation & the health professions.

[24]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[25]  Noah Kiwanuka,et al.  Mortality associated with HIV infection in rural Rakai District, Uganda , 2000, AIDS.

[26]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[27]  J. Kaewkungwal,et al.  Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. , 2000, The Journal of infectious diseases.

[28]  N. French,et al.  Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. , 1999, Journal of acquired immune deficiency syndromes.

[29]  C. Khamboonruang,et al.  Risk factors for HIV‐1 transmission from HIV‐seropositive male blood donors to their regular female partners in northern Thailand , 1997, AIDS.

[30]  J. Whitworth,et al.  HIV-1 disease progression and AIDS-defining disorders in rural Uganda , 1997, The Lancet.

[31]  M. Wawer,et al.  Trends in HIV‐1 prevalence may not reflect trends in incidence in mature epidemics: data from the Rakai population‐based cohort, Uganda , 1997, AIDS.

[32]  J. Whitworth,et al.  An HIV‐1 natural history cohort and survival times in rural Uganda , 1997, AIDS.

[33]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[34]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[35]  M. Zwahlen,et al.  Progression and mortality of untreated HIV-positive individuals living in resource-limited settings : Update of literature review and evidence synthesis , 2006 .

[36]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .